A new cell ther­a­py start­up from an im­munother­a­py pi­o­neer rais­es $175M in KRAS quest

Among the tus­sle in the biotech space to fi­nal­ly “solve” sol­id tu­mors, a qui­et biotech is now tak­ing its shot — and has some VCs and some big-name sci­en­tif­ic prowess from Fred Hutch to back up its ef­forts.

Affi­ni-T Ther­a­peu­tics, apt­ly named for its em­pha­sis on T cell ther­a­py and armed with 57 em­ploy­ees across two lab spaces in Seat­tle and Boston, raised $175 mil­lion Tues­day to spend as the biotech sees fit — which at this point means build­ing up its dis­cov­ery plat­form and push­ing can­di­dates from its pipeline in­to clin­i­cal tri­als. Ac­cord­ing to the CEO, that mon­ey should last the com­pa­ny through De­cem­ber 2024, or about three years.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN